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Abstract
Objectives—The current psoriatic arthritis (PsA) Core Domain Set defines core domains to be 
measured in randomized controlled trials (RCTs) and longitudinal observational studies (LOS) and 
was published in 2006. At the Outcome Measures in Rheumatology (OMERACT) meeting in 
2014, researchers, clinicians and patients unanimously voted for updating the PsA Core Domain 
Set to include the patient perspective in accordance with OMERACT Filter 2.0. Herein we report 
the proceedings of the PsA Workshop at the OMERACT meeting in 2016 including studies 
presented in the plenary, results of breakout group discussions, and final voting and endorsement 
of the 2016 updated PsA Core Domain Set.
Methods—We conducted research to develop the updated PsA Core Domain Set. At OMERACT 
2016 this work was presented, discussed in breakout groups and the updated PsA core domain set 
was voted on and endorsed by OMERACT participants.
Results—The updated PsA Core Domain Set includes: musculoskeletal disease activity, skin 
disease activity, fatigue, pain, patient global, physical function, health related quality of life and 
systemic inflammation which are recommended for all RCTs and LOS). Economic cost, emotional 
well-being, participation and structural damage are important but not required in all RCTs and 
LOS. Independence, sleep, stiffness and treatment burden on the research agenda.
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Conclusion—The updated PsA Core Domain Set was endorsed at OMERACT 2016. Next steps 
for the PsA working group include evaluation of available outcome measures for each of the core 
domains and development of a PsA core outcome measurement set.
Key indexing terms
psoriatic arthritis; core set; outcome measures
INTRODUCTION
STATEMENT OF CONTRIBUTION TO THE LITERATURE: This paper describes the 
the research work streams that led to the updated PsA Core domain set and its final 
endorsement at OMERACT 2016. The 2016 updated PsA Core Domain Set will allow the 
beginning of patient-centered and evidence-based selection of a Core Outcome 
Measurement set for future PsA clinical trials. This paper uniquely describes the 
OMERACT 2016 conference process which led to the endorsement of the final updated 
2016 PsA Core domain set and has not been submitted elsewhere.
The updated 2016 PsA Core Domain Set contains the following revised or new domains 
compared to the 2006 core set:
• MSK disease activity (revised to include peripheral joints, dactylitis, enthesitis 
and spine symptoms)
• Skin activity (revised to include skin and nails)
• Fatigue
• Systemic inflammation.
• Participation, Emotional well-being, Structural damage and Economic cost are 
designated important and are not required in all clinical trials.
The purpose of disease core sets is to standardize measurement and reporting of outcomes in 
randomized controlled trials (RCTs) and longitudinal observational studies (LOS). 
Implementation and reporting of disease core sets in RCTs is key to generating high quality 
evidence to support useful treatment recommendations (1). Outcome Measures in 
Rheumatology (OMERACT) pioneered disease core set development and refined their 
methodology based on evidence (2, 3). In 2014, OMERACT presented and published Filter 
2.0 outlining a methodologically rigorous process for defining core domain sets (5) based on 
early inclusion of the views of key stakeholders, especially patients and iterative, evidence-
driven consensus among stakeholders. At the OMERACT 2014 conference, participants 
recognized the need to update the PsA Core Domain set based on the new OMERACT filter 
and, integral to this process, to incorporate the voice of patients and rapidly developing 
scientific knowledge about the disease and the measurement of PsA (6, 7). OMERACT 2014 
attendees (including researchers, patient partners and clinicians) voted to update the PsA 
core domain set (100% voted yes) and additionally voted to include fatigue (72%) and 
dactylitis (70%) in the core set (8).
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Since the OMERACT 2014 meeting, the GRAPPA-OMERACT PsA working group 
conducted research projects (9) to identify domains important to patients and physicians for 
the PsA core domain set update. This paper summarizes results presented at the OMERACT 
2016 PsA workshop and breakout group discussions and the subsequent endorsement of the 
updated PsA core domain set.
Summary of research conducted in preparation for OMERACT 2016
The PsA working group conducted the following research projects: 1) a systematic literature 
review (SLR) in Pubmed and EMBASE to identify domains measured in PsA RCTs, LOS 
and registries; 2) international focus groups with patients with PsA to identify domains; 3) 
international patient and physician surveys; and 4) a consensus meeting held March 12, 2016 
in Jersey City, NJ, US with patients and physicians using the nominal group technique 
(NGT) to draft a PsA core domain set. Detailed methods and results are presented in 
separate manuscripts (9, 10) (reference to be added later).
Studies were approved by the Johns Hopkins Institutional Review Board (IRB), Baltimore, 
MD, USA (IRB00093948 and NA_00066663), the National Research Ethics Service 
Committee North West – Haydock, UK (REC reference: 15/NW/0609) and the online survey 
study was accorded exempt status at the University of Pennsylvania IRB, Philadelphia, PA, 
USA.
The SLR has been published and showed the measurement of the complete 2006 PsA core 
domain set increased from being performed in 24% of RCTs (from 2005 to 2010) to 59% of 
RCTs (from 2010 to 2015) (10, 11). Twenty-four domains were identified from the SLR, 
with 18 measured in addition to the core set (Figure 1). The changes over time are likely 
related to dissemination of the PsA core set, recognition of the importance of fatigue, 
productivity and other aspects of life impact for patients (8, 12–14), and availability of 
outcome measures for domains such as dactylitis (15).
Qualitative research was conducted to identify domains directly from patients to include 
their perspective at the inception of the process (16). Two focus group studies were 
conducted: one international (16 focus groups with 89 patients in total in Australia, Brazil, 
France, Netherlands, Singapore and US) and one multicenter study in the UK (8 focus 
groups with 41 patients). Qualitative data analysis of each study identified patient domains. 
Across both studies there were 34 unique patient domains.
The 24 domains from the SLR and 34 domains from international focus groups were then 
combined into a list of 39 unique domains. Patients (n=50) recruited from rheumatology 
clinics and patient organizations and physicians (n=75) recruited through GRAPPA rated 
domains via electronic surveys running in parallel. Results were discussed at the NGT 
consensus meeting held March 12, 2016 with 12 patients and 12 physicians. The NGT 
method allowed stakeholders to prioritize items ensuring the inclusion of all participants’ 
opinions (17). At the end of the consensus meeting a draft core domain set was agreed upon 
and included 10 domains: musculoskeletal (MSK) disease activity (peripheral joints, 
enthesitis, dactylitis and spine symtoms), skin disease activity (skin and nails), pain, patient 
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global (patient reported disease related health status), physical function, participation, 
emotional well-being, fatigue, systemic inflammation, structural damage (to be measured at 
least once during a new drug development program for PsA). A domain considered 
important but not required in all RCTs and LOS was economic cost (societal financial 
impact not otherwise captured by participation and work/employment domains). The NGT 
core domain set was then rated in a second electronic survey completed in parallel by 
patients and physicians. Based on results from the second round of surveys the draft core 
domain set included nine domains: MSK disease activity, skin disease activity, pain, patient 
global, physical function, participation, fatigue, systemic inflammation, structural damage 
(to be measured at least once during a new drug development program for PsA) (Table 1).
Patients were involved at all levels as research participants, patient researchers (conducting 
focus groups and analyzing data), or patient research partners (PRPs; assisting in the high 
level conduct of the research) in each of the work streams (Table 2). One PRP was a member 
of the steering committee for the working group (reference to be added later).
Working group meeting at OMERACT 2016
A working group meeting was held at OMERACT prior to the PsA Workshop for final 
review of the workshop presentation, breakout group organization and voting questions. At 
this meeting decisions were made regarding the core domain set to be presented at the 
workshop:
1. Structural damage was important but not required in all RCTs and LOS. This 
was congruent with the NGT meeting where structural damage was 
recommended to be measured once during the development of a new therapeutic 
agent for PsA but not required in all RCTs.
2. Health related quality of life (HRQoL) remained a core domain required in all 
RCTs and LOS based on its presence in the 2006 core domain set.
3. The group decided to hold two separate votes for participation: first for inclusion 
in the core domain set (required in all RCTs and LOS) and second (if first not 
agreed by 70%) for inclusion in the middle circle (important but not required in 
all RCTs and LOS). Work/employment (included in participation) was rated high 
in the first survey by both patients and physicians, and participation was in the 
preliminary core set after the NGT meeting as well as rated high by patients in 
the second survey. However, due feasibility concerns and overlap of participation 
with the broader concept of HRQoL, we anticipated both may not be accepted in 
the core set (and therefore the decision to hold two votes).
4. Due to the importance of emotional well-being for patients, both in the NGT 
meeting and also at this working group meeting, the group similarly decided to 
first vote for inclusion of emotional well-being in the core set and second (if first 
not agreed by 70%) vote for inclusion in the middle circle.
The group also agreed upon the final list of voting questions for the conclusion of the 
workshop.
Orbai et al. Page 5
J Rheumatol. Author manuscript; available in PMC 2017 October 03.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
OMERACT 2016 PsA workshop
The PsA workshop began with presentation of results, continued with eight breakout group 
discussions running in parallel followed by reports from each breakout group, and concluded 
with voting. Results from research conducted in preparation for OMERACT were presented 
to workshop participants as above (Table 1).
Breakout group discussions were facilitated by two people (one moderator and one reporter), 
both of whom were either a member of the working group or experienced PsA or psoriasis 
researchers. The four PsA working group PRPs were either a group moderator or reporter. 
All breakout groups discussed each new or updated domain: participation, systemic 
inflammation, MSK disease activity and skin activity, emotional well-being and structural 
damage. Fatigue had been voted for inclusion in the core domain set by 72% of the 
participants at the OMERACT 2014 conference (8) and was not discussed again. For each 
domain breakout group participants were asked to provide arguments supporting inclusion in 
the core domain set as well as perceived challenges. Throughout the process of developing 
the core set and also in the breakout groups, discussion of how to best measure a particular 
domain was discouraged as instruments were not felt to be relevant at this stage to the 
decision on which domains to include. A summary of breakout group discussions is 
presented in supplement Table 3.
Following the breakout group reporting in the plenary, OMERACT participants voted for 
individual domains and this concluded the workshop (Table 4). The only modification to the 
preliminary core set was movement of participation to the middle circle (important but not 
required in all RCTs and LOS).
OMERACT 2016 Final Plenary
At the OMERACT plenary the final PsA 2016 Core Domain Set was proposed for 
endorsement and achieved consensus with a 90% vote from 130 participants at the 
conference. The updated 2016 PsA core domain set includes the following outcomes 
recommended for assessment in all RCTs and LOS (inner core): MSK disease activity, skin 
disease activity, fatigue, pain, patient global, physical function, HRQoL and systemic 
inflammation. The following outcomes (middle circle) are important but not required in all 
RCTs/LOS: economic cost, emotional well-being, participation and structural damage. 
Outcomes that need to be studied further due to their importance for people with PsA 
include: independence, sleep, stiffness and treatment burden (Figure 2).
Contextual factors for PsA are another important area that needs further study. Adverse 
events are measured in every RCT and are part of the OMERACT outcome framework. The 
updated 2016 PsA Core Domain Set addresses all areas of the OMERACT Filter 2.0 
framework (Figure 3).
DISCUSSION
Psoriatic arthritis is a heterogeneous disease with tremendous impact on patients’ lives. At 
OMERACT 2014 the GRAPPA-OMERACT PsA working group committed to updating the 
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2006 PsA Core Domain set to incorporate the input of people living with PsA and advances 
in the field. Candidate domains for the updated PsA Core Domain Set were obtained directly 
from patients through international focus groups and an SLR of outcomes measured in PsA 
RCTs, LOS and registries. During the surveys and consensus meeting with patients and 
physicians, each domain presented for rating or discussion was accompanied by a clear 
definition based on focus group patient participants’ descriptions and reviewed by the 
working group including PRPs. We adopted this method to maximize understanding for all 
participants and to minimize subjective interpretations during the surveys and the consensus 
meeting.
The concept of MSK disease activity which encompasses peripheral joints, enthesitis, 
dactylitis and spine symptoms has been initially suggested in breakout groups at OMERACT 
2014 (8) out of concerns for parsimony in the core set. This comprehensive definition for 
MSK disease activity was fully supported at the consensus meeting with patients and 
physicians and endorsed with majority vote at OMERACT 2016.
Discussion at OMERACT 2016 focused particularly on the inclusion of participation and 
emotional well-being. Participation (encompassing work and/or employment within and 
outside the home, leisure activities, social activities and family roles) was defined congruent 
with the ICF definition which is “involvement in a life situation” and distinct from activity 
which implies “the execution of a task or action” (18). Ability to perform work (both paid 
and unpaid) is an important outcome to patients and ranked highly in surveys with patients 
conducted by our working group and also in the European League Against Rheumatism 
(EULAR) led Psoriatic Arthritis Impact of Disease (PsAID) study (12). Estimates of 
unemployment and work disability range from 20–50% and 16–39% respectively in clinical 
trials and cohort studies (19) and appropriate therapy can improve aspects of participation 
(20). Therefore participation has face validity and optimal measurement needs to be studied 
further.
Emotional well-being was defined as “feeling good about oneself” and may include 
additional domains such as depressive mood, anxiety, embarrassment, self-worth, 
frustration, and stress. During the NGT meeting, emotional well-being was highly relevant 
to the management of PsA for patient participants. Previous studies suggested 20% of 
patients with PsA have depression and one study found that 37% had anxiety (21). The best 
way of measuring emotional well-being in patients with PsA has not been investigated. The 
PsAID includes items on depression, anxiety and embarrassment and the Medical Outcomes 
Survey Short Form-36 (SF-36) includes “mental health”, “role emotional”, “vitality” and 
also “social functioning” domains (22). Following discussions at OMERACT 2016, and in 
line with the second survey with patients and physicians it became clear that additional 
research may be needed before emotional well-being might become an inner core element.
An aspect discussed for both participation and emotional well-being was conceptual overlap 
with HRQoL. Concomitant measurement of all these concepts may be redundant and 
demanding on responders. Another consideration is that patient participants in focus groups 
described specific areas of PsA life impact. For this reason, for patients it may be difficult to 
relate to overarching concepts like HRQoL when considering their treatment options. There 
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was discussion to replace the generic construct of HRQoL with explicit domains that are 
patient relevant: participation, fatigue and emotional well-being. This is an important area 
for future research in PsA.
One concern raised at OMERACT 2016 was the number of domains and subdomains 
mandatory in all future PsA RCTs and LOS. PsA is a highly heterogeneous disease and 
measuring only one part may be misleading or lead to limited information for patients and 
clinicians. Importantly, most of these domains are currently being measured in RCTs (9). 
However, examination for areas of overlap is important to decrease redundancy.
Next steps include investigation of instruments available to measure the Core Domain Set. 
We are beginning this process with an SLR of instruments for each core domain. We will 
investigate psychometric properties of available instruments such as face and content 
validity (including match with the domain of interest) and feasibility as a part of the recently 
described OMERACT decision making process for selection of outcome measures or “the 
eyeball test” (23). Focus groups will take into account patient’s impressions of the 
instruments. We will simultaneously examine instrument construct validity and 
responsiveness in RCT datasets and LOS currently in progress. These work streams will 
inform the development of a PsA Core Outcome Measurement set.
Additionally, the research agenda included items of importance to patients: independence, 
sleep, stiffness and treatment burden. These domains need further study of their contribution 
to PsA assessment.
In summary, the updated PsA Core Domain set incorporates patient input, scientific 
knowledge on pathophysiologic manifestations and measurement of disease in PsA, and the 
broad life impact of PsA. Next steps include development of a PsA Core Outcome 
Measurement set for RCTs and LOS.
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Figure 1. 
Domains are shown on the X axis with proportion of studies measuring each domain on the 
Y axis. The black mark designates 2006 PsA core domains. RCT: randomized controlled 
trials; LOS: longitudinal observational studies; HRQL: health-related quality of life; MD: 
physician; MRI: magnetic resonance imaging; US: ultrasound.
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Figure 2. 
Updated 2016 PsA Core Domain Set. MSK disease activity includes peripheral joints, 
enthesitis, dactylitis, and spine symptoms. Skin activity includes skin and nails. PtGA is 
defined as patient-reported diseaserelated health status. The inner circle includes domains 
recommended for measurement in every RCT and LOS. The middle circle includes domains 
that are important, but not required in every RCT and LOS. The outer circle contains 
domains that may be important, but need further study. PsA: psoriatic arthritis; MSK: 
musculoskeletal; PtGA: patient’s global assessment; RCT: randomized controlled trial; LOS: 
longitudinal observational studies. Reproduced with permission from Orbai, et al. Ann 
Rheum Dis 2016 Dec 13(E-pub ahead of print).
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Figure 3. 
Updated PsA Core Domain Set and corresponding OMERACT core areas. Domains in bold 
face are in the core set (to be measured in all RCT), and domains in plain font are in the 
middle circle (highly recommended, but not mandatory). PsA: psoriatic arthritis; 
OMERACT: Outcome Measures in Rheumatology; RCT: randomized controlled trial; 
HRQOL: health-related quality of life; MSK: musculoskeletal. From Boers M, et al. J Clin 
Epidemiol 2014;67:745-53; adapted with permission.
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Table 1
Domains in the 2006 PsA Core Domain Set and candidate domains for the updated core set
OMERACT 2006
PsA Core
Domain Set
OMERACT 2014
voted (≥70%)
inclusion in
the core set
Draft core domain set
at the end of the NGT*
meeting 2016
Draft core set after
the 2nd patient and physician
survey**
Peripheral joint activity Dactylitis MSK disease activity MSK disease activity
Skin activity Skin disease activity Skin disease activity
Pain Pain Pain
Patient global Patient global Patient global
Physical function Physical function Physical function
HRQoL
Participation Participation
Emotional well-being
Fatigue Fatigue Fatigue
Systemic inflammation Systemic inflammation
Structural damage *** Structural damage ***
*NGT nominal group technique meeting,
**during the second survey patients and physicians rated the importance of domains proposed after the NGT meeting – emotional well-being was 
moved out of the core as less than 70% of either physician or patient respondents rated it as at least 8 on a scale from 0–10,
***
structural damage was recommended for assessment at least once during the development of a new drug for PsA.
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Table 2
Patients involved in the PsA Core Domain Set update
Country International patient
focus group
participants
Qualitative data
analysis (patient
researchers, PRPs)
Survey participants Nominal group
technique patient
participants and
PRPs
Australia 7
Brazil 12 1 1
Canada 1 1 2
France 12 4
Hong Kong 1
Ireland 9 1
Italy 1
Netherlands 17 2 1 1
Norway 1 1
Romania 1
Singapore 13 8
Spain 1
UK 41 2 3 1
USA 27 1 18 4
Total 129 6 50 12
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Table 3
Summary of core domain discussion during PsA workshop breakout groups at OMERACT 2016
Domain Support inclusion Challenges Suggestions
Structural damage Important aspect of medication
efficacy for PsA. Keep a special
status in the middle core with
requirement to be measured at least
once during the development
program of a new drug for PsA.
Not feasible to require in all
RCTs. Small changes if any
(no responsiveness) in short
clinical trials.
Combining modalities of
assessment is important.
Measurement instruments
may concomitantly assess
damage, inflammation and
disease activity
Systemic inflammation Important, majority in all groups
supported inclusion. Also very
important in longitudinal studies due
to link with heart disease and
potentially other comorbidities.
- When considering
instruments also consider
imaging for this domain
Emotional well-being Very important to patients: important
in qualitative research and patient
surveys. Psychological distress is
frequent in both psoriasis and
psoriatic arthritis. Together with
participation and fatigue an
appropriate replacement for HRQoL.
Feasibility concern and
concern over necessity in
every RCT. Multifactorial
concept potentially
overlapping with patient
global and fatigue. How is it
different from HRQoL? This
could be an important/key
contextual factor.
We need to better
understand overlap with
patient global and HRQoL.
We also need to find
instruments for assessment.
Emotional well-being should
be examined as a
contextual factor.
MSK disease activity Majority agreement with the updated
comprehensive MSK disease
activity. Easily comprehensible as a
domain even for non-
rheumatologists.
Inclusion of spine symptoms
within MSK disease activity
is challenging due to the lack
of good instruments to
assess activity; additionally,
measuring spine symptoms
in all trials is not currently
feasible. Some preferred the
individual components be
considered instead of the
broader domain of MSK
disease activity.
Participation Face validity: important to patients
and physicians, shows ability to “live
one’s life”. A common discussion
point was that participation is really
at the core of why we treat patients:
to improve their function in their
daily lives. Participation can be
measured and it is responsive. Work
and employment are very important
for patients. This is distinct from
physical function. However, this is
also more than just work and
includes social and leisure activities.
The definition as proposed is
broad. There was a concern
for overlap with HRQoL and
physical function, and it may
be influenced by emotional
well-being. Concern for
redundancy if also including
HRQoL in inner core. Some
thought it should be one or
the other.
Include in the inner core
and move HRQoL in the
middle circle. Study the
independent contribution of
the domain in explaining
PsA variability; and overlap
with other domains.
Skin disease activity Majority agreement, important to
patients and physicians
Some concerned about
feasibility of measuring in all
RCTs
Patient global
assessment
Always measured Problematic to pinpoint the
exact concept behind this
domain
The patient global needs to
be addressed among all
diseases and should be
further studied.
Physician global N/A Felt to be captured in MSK
disease activity. Potentially
subject to bias.
Proposed core set Felt to be comprehensive. A
strength is that most of these
domains are already measured in
clinical trials.
Some participants felt the
core set contained too many
domains, potentially limiting
feasibility. There was a
concern for responder
burden at the measurement
stage.
Examine PROMIS
measures
Examine redundancies
among domains.
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